In Q1 2025, Avoro Capital Advisors held 31 positions worth $6.2B. They initiated 1 new position and exited 31. Their largest holding was UTHR ($824.6M). Portfolio value shrank -10.0% versus the prior quarter.
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q1 2025?
Avoro Capital Advisors held 31 biotech stocks in their 13F portfolio in Q1 2025. Their top positions include UTHR, ASND, ARGX, MDGL, KRYS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q1 2025?
Avoro Capital Advisors's tracked biotech portfolio was worth $6.2B across 31 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q1 2025?
Avoro Capital Advisors initiated 1 new position in Q1 2025, including CNTA. They also increased 11 existing positions.
What did Avoro Capital Advisors sell in Q1 2025?
Avoro Capital Advisors fully exited 31 positions in Q1 2025, including CBAY, MCRB, TNGX, DSGN, MRSN and 26 more. They also trimmed 7 existing positions.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisorsportfolio →